



## **Mylan Receives \$37.5 Million and Settles All Outstanding Disputes With Schwarz Pharma's KUDCo and Related Parties**

PITTSBURGH, June 25 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced that it has settled all claims in the patent litigation pending between Mylan Pharmaceuticals Inc. and Kremers Urban Development Company and Schwarz Pharma's various other U.S. subsidiaries. Under the settlement, Kremers Urban shall pay Mylan and its Spanish-based development partner, Esteve Quimica S.A., a total of \$50 million (U.S.), with Mylan receiving approximately \$37.5 million (U.S.). A portion of the payment will be for reimbursement of legal fees and expenses. Mylan and Esteve filed suit against Kremers Urban and other Schwartz Pharma affiliates in Wilmington, Delaware in 2002, and Kremers Urban filed suit against Mylan and Esteve in Washington, DC in 2003. The settlement resolves both suits and any claims with regard to each company's omeprazole and other proton pump inhibitor process and formulation patents on a world-wide basis, and also ends a related arbitration proceeding in Spain.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit [www.mylan.com](http://www.mylan.com) .

This press release includes statements that constitute "forward-looking statements", including with regard to the settlement agreement and the anticipated payment to Mylan and Esteve. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: a party's breach of the settlement agreement, including by failing to file appropriate stipulations of dismissal formally ending the court actions; a decision by the court to rescind the dismissal from the litigation; the possibility that the plaintiffs ultimately might re-file the same claims and be granted injunctive relief or money damages; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.

06/25/2004

CONTACT:

Media, Heather Bresch  
or Investors, Kris King  
of Mylan Laboratories Inc.

+1-724-514-1800

Web site: <http://www.mylan.com>